Vicarius Pharma lands $21.8 mln

Switzerland-based Vicarius Pharma AG, which provides U.S.-based biopharmaceutical companies a "novel approach" to commercializing assets in European markets, has raised $21.8 million in funding. James Mullen, CEO of Patheon and former CEO of Biogen, was the lead investor.

North AmericaUSBriefs